Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse

Antagonistic properties of buprenorphine for epsilon- and micro -opioid receptors were characterized in beta-endorphin- and [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO)-induced antinociception, respectively, with the tail-flick test in male ICR mice. epsilon-Opioid receptor agonist beta-endorphin (0.1-1 micro g), micro -opioid receptor agonist DAMGO (0.5-20 ng), or buprenorphine (0.1-20 micro g) administered i.c.v. dose dependently produced antinociception. The antinociception induced by 10 micro g of buprenorphine given i.c.v. was completely blocked by the pretreatment with beta-funaltrexamine (beta-FNA) (0.3 micro g i.c.v.), indicating that the buprenophine-induced antinociception is mediated by the stimulation of the micro -opioid receptor. The antinociceptive effects induced by beta-endorphin (1 micro g i.c.v.) and DAMGO (16 ng i.c.v.) were dose dependently blocked by pretreatment with smaller doses of buprenorphine (0.001-1 micro g i.c.v.), but not by a higher dose of buprenorphine (10 micro g i.c.v.). beta-FNA at a dose (0.3 micro g i.c.v.) that strongly attenuated DAMGO-induced antinociception had no effect on the antinociception produced by beta-endorphin (1 micro g i.c.v.). However, pretreatment with buprenorphine (0.1-10 micro g) in mice pretreated with this same dose of beta-FNA was effective in blocking beta-endorphin-induced antinociception. beta-FNA was 226-fold more effective at antagonizing the antinociception induced by DAMGO (16 ng i.c.v.) than by beta-endorphin (1 micro g i.c.v.). The antinociception induced by delta-opioid receptor agonist [d-Ala2]deltorphin II (10 micro g i.c.v.) or kappa1-opioid receptor agonist trans-3,4-dichloro-N-methyl-N-(2-[1-pyrrolidinyl]cyclohexyl)benzeneacetamine methanesulfonate salt [(-)-U50,488H] (75 micro g i.c.v.) was not affected by pretreatment with buprenorphine (0.1-1.0 micro g i.c.v.). It is concluded that buprenorphine, at small doses, blocks epsilon-opioid receptor-mediated beta-endorphin-induced antinociception and micro -opioid receptor-mediated DAMGO-induced antinociception, and at high doses produces a micro -opioid receptor-mediated antinociception.     

Effects of serotonin receptor antagonists on punished responding maintained by stimulus-shock termination or food presentation in squirrel monkeys

The behavioral effects of a series of serotonin (5-HT) receptor antagonists were examined on punished performances maintained by termination of a stimulus correlated with shock (stimulus-shock termination) or by food presentation in squirrel monkeys. Intramuscular administration of metergoline (0.03-0.3 mg/kg), methysergide (0.1-1.0 mg/kg), cyproheptadine (0.1-1.0 mg/kg), mianserin (0.1-10 mg/kg) and cinanserin (1.0-3.0 mg/kg) increased punished responding under the stimulus-shock termination and food schedules. The 5-HT2-selective receptor antagonist pirenperone (0.001-0.3 mg/kg) and the 5-HT2 receptor ligand spiperone (0.001-0.1 mg/kg) did not increase punished responding maintained by either event. In contrast, the prototype 5-HT2 ligand ketanserin increased punished responding maintained by food at doses (i.e., 0.1-3.0 mg/kg) that only decreased behavior maintained by stimulus-shock termination. Highly significant correlations were found between the peak rate-increasing effects of the 5-HT antagonists on punished responding maintained by stimulus-shock termination and their reported affinities at 5-HT1 (r = 0.99) and 5-HT2 (r = 0.95) binding sites. In contrast, under the food schedule a significant correlation was found only between the peak rate-increasing effects of the 5-HT antagonists and their reported affinities for the 5-HT1 site (r = 0.87). These findings confirm the involvement of serotonergic pathways in punishment-suppressed operant behavior and suggest that different populations of 5-HT receptors modulate punished behavior maintained by different types of consequent events (i.e., stimulus-shock termination or food).     

Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity

Two corticotropin-releasing factor (CRF) receptor families have been identified (CRF1 and CRF2). Whereas anxiogenic-like roles for the CRF1 receptor have been identified, behavioral functions of the CRF2 receptor remain obscure. Urocortin 2 (Ucn 2), a CRF-related peptide that selectively binds CRF2 receptors, was recently identified and recognized for its central anorectic properties. The present study tested the hypothesis that the anorexigenic mode of action of Ucn 2 differed from that of ovine CRF (oCRF), a preferential CRF1 receptor agonist. The behavioral effects of intracerebroventricular administration of Ucn 2 were compared with those of oCRF in nondeprived male Wistar rats (n=102). Ucn 2 reduced 6-h food and water intake at doses that did not induce visceral illness (0.1, 1, and 10 microg), as indicated by kaolin intake. Ucn 2 retained its potent anorectic activity in rats receiving a highly palatable cafeteria diet, preferentially reducing intake of carbohydrate (CHO)-rich items while sparing intake of mixed-fat/CHO items. In contrast to Ucn 2, oCRF (10 microg) suppressed 6-h intake of cafeteria diet-fed rats without regard to macronutrient composition. Rather, oCRF most potently suppressed intake of preferred food items. Whereas oCRF had short-onset motor-activating effects, Ucn 2 had nondose-dependent, delayed-onset motor-suppressing effects. Thus, central infusion of a CRF2 receptor agonist suppressed intake of both bland and palatable diets without inducing behavioral arousal or malaise, and the profile of anorexigenic effects qualitatively differed from those of a CRF1 receptor agonist. The results suggest the existence of distinct forms of CRF1- and CRF2-mediated anorexia.     

Effects of serotonin receptor agonists and antagonists on schedule-controlled behavior of squirrel monkeys

The behavioral effects of the serotonin (5-HT) precursor l-5-hydroxytryptophan (l-5-HTP) and the phenylpiperazine 5-HT agonists 6-chloro-2-(1-piperazinyl)pyrazine (MK-212), 1-(m-trifluromethylphenyl) piperazine (TFMPP), 1-(m-chlorophenyl)piperazine (CPP) and 2-(1-piperazinyl)quinoline (quipazine) were compared with those of the putative 5-HT antagonists metergoline, methysergide, cyproheptadine, cinanserin and ketanserin under a multiple 5-min fixed-interval schedule of food or electric shock presentation in squirrel monkeys. Intramuscular administration of l-5-HTP (0.3-17 mg/kg), MK-212 (0.01-1.0 mg/kg), TFMPP and CPP (0.03-10 mg/kg) produced dose-related decreases in responding under both the food- and shock-presentation schedules. Quipazine differed from the other 5-HT agonists in that it increased shock-maintained behavior at doses (0.1-1.0 mg/kg) that decreased responding maintained by food. The 5-HT antagonists produced mixed behavioral effects. Metergoline (0.03-1.0 mg/kg), cyproheptadine (0.1-1.0 mg/kg) and cinanserin (1.0-10 mg/kg) produced dose-related increases in responding maintained by food, whereas only metergoline and methysergide increased behavior maintained by shock presentation. The prototype 5-HT2-receptor ligand ketanserin (0.3-10 mg/kg) differed from the other 5-HT antagonists in that it decreased behavior maintained by either event. Thus, performances maintained by food or shock presentation reveal both qualitative and quantitative differences in the behavioral effects of 5-HT receptor agonists and antagonists.     

Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral,but not endocrine,response to environmental stress

Corticotropin-releasing factor (CRF) is one of the principle components of the stress response. The physiological effects of CRF are mediated by two receptor subtypes, CRF(1) and CRF(2). Recent data obtained with the selective CRF(2) antagonist antisauvagine-30 (ASV-30) has begun to suggest that both CRF receptor subtypes may play a role in stress-related behaviors. Exactly how these two receptor subtypes interact to modulate the behavioral and endocrine responses to stress is not clear, however. We have attempted to understand the role of the CRF(2) receptor in the behavioral and endocrine responses to stress by comparing the effects of ASV-30 with the mixed CRF(1)/CRF(2) receptor antagonist astressin. Centrally administered ASV-30 reduced anxiety-like behavior in BALB/c mice in three models of anxiety: marble burying [minimal effective dose (MED) = 3 nmol], open field (MED = 3 nmol), and elevated plus maze (MED = 0.1 nmol). ASV-30 did not change locomotor activity or the adrenocorticotropic hormone (ACTH) response to restraint stress. The potent mixed CRF(1)/CRF(2) antagonist astressin not only reduced anxiety-like behavior in all three models with equivalent potency but also blunted the ACTH response to restraint stress. Finally, the new selective CRF(2) receptor agonist urocortin-II produced a dose-dependent increase in anxiety-like behavior in the plus maze test. Therefore, our data suggest that the CRF(2) receptor plays a role in the behavioral, but not the hypothalamic-pituitary-adrenal axis, response to stress.     

Common mechanisms underlying the proconflict effects of corticotropin-releasing factor, a benzodiazepine inverse agonist and electric foot-shock.

The effects of corticotropin-releasing factor (CRF), a benzodiazepine inverse agonist (methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate; DMCM) and electric foot-shock on rat conflict behavior were characterized and compared. Rats were trained to lever press under a multiple fixed-ratio schedule (FR 20) of food reinforcement in which responses during the first component were not punished, and the first response of each FR during the second component produced electric shock of an intensity sufficient to suppress responding by 10% to 15%. Intracerebroventricular injection of CRF (0.1-5.6 micrograms) caused a dose-dependent decrease in the rate of responding in both components of the schedule. However, CRF was more potent in decreasing rates of punished responding (proconflict effect). DMCM (10-100 micrograms; i.c.v.) also decreased rates of punished and nonpunished responding and was more potent during the punishment component. The suppression of punished and nonpunished responding by CRF and DMCM was mimicked by increasing the shock intensity (delta = 0.1 to 0.6 mA) during the punishment component. To determine whether CRF, DMCM and electric shock shared common mechanisms for these effects, rats were pretreated with i.c.v. injections of either a CRF antagonist (alpha helical CRF9-41, 50 micrograms), a benzodiazepine agonist (chlordiazepoxide, 10 micrograms) or a benzodiazepine antagonist (flumazenil, 10 micrograms) before the administration of equieffective doses of CRF or DMCM or an increase in shock intensity. Chlordiazepoxide attenuated the effects of all three stimuli. Flumazenil antagonized DMCM and CRF, but not shock, implicating a pharmacologic interaction between CRF and benzodiazepine systems.(ABSTRACT TRUNCATED AT 250 WORDS)     

Acute and chronic corticotropin-releasing factor 1 receptor blockade inhibits cocaine-induced dopamine release: correlation with dopamine neuron activity

Corticotropin-releasing factor (CRF) is a neuropeptide associated with the integration of the physiological and behavioral responses to stress. Recently, CRF1 receptor antagonists have been shown to decrease cocaine self-administration and inhibit stress-induced reinstatement of cocaine-seeking behavior. The exact mechanisms underlying this effect are not clear. Based on the large amount of literature demonstrating an association between dopaminergic neurotransmission and reward-related behavior, the aim of the present study was to examine the effects of acute versus chronic CRF1 receptor blockade on mesencephalic dopamine (DA) neuron activity (determined by in vivo extracellular recordings) and extracellular DA levels in the nucleus accumbens (Acb) (using in vivo microdialysis). In addition, the effect of CRF1 receptor antagonism on cocaine-induced DA overflow in the Acb was examined and correlated with DA neuron activity in the ventral tegmental area (VTA). Acute (but not chronic) CRF1 receptor blockade by CRA-0450 [1-[8-(2,4-dichlorophenyl)-2-methylquinolin-4-yl]-1,2,3,6-tetrahydropyridine-4-carboxamide benzenesulfonate] was found to significantly increase DA neuron population activity without affecting burst firing, average firing rate, or Acb DA levels. In addition, both acute and chronic CRF1 receptor antagonism significantly reduced cocaine-stimulated DA overflow in the Acb, and this reduction was correlated with an attenuated cocaine-induced inhibition of DA population activity. Taken as a whole, these data demonstrate that, although DA neuron population activity exhibits tolerance to chronic CRF1 receptor antagonism (by CRA-0450), tolerance does not develop to the selective inhibition of cocaine-induced DA release (in the Acb) and, as such, may be beneficial in the treatment of cocaine addiction.     

Presence of diadenosine polyphosphates in the aqueous humor: their effect on intraocular pressure

Adenine dinucleotides are present in many biological systems and may serve as physiological regulators of processes such as neurotransmitter release, vascular tone or corneal hydration. The presence of diadenosine polyphosphates was investigated in New Zealand White rabbit aqueous humor. Diadenosine tetraphosphate (Ap4A) and diadenosine pentaphosphate (Ap5A) were identified and quantified in the aqueous humor with concentrations of 0.34 +/- 0.1 and 0.08 +/- 0.01 microM, respectively. The effects of topical corneal application of diadenosine pyrophosphate (Ap2A), diadenosine triphosphate (Ap3A), Ap4A, and Ap5A on intraocular pressure in rabbits were also studied. Ap2A, Ap3A, and Ap5A increased intraocular pressure with threshold doses of approximately 0.1 to 1.0 micro g. 10 microl(-1). Ap4A decreased intraocular pressure with an IC50 value of 0.12 micro g. 10 microl(-1) (or 0.13 nmol). Cross-desensitization studies suggested the activation of a P2X receptor for the hypotensive effect of Ap4A and a P2Y receptor in the case of Ap5A. The ATP receptor antagonists (all 100 micro g. 10 microl(-1)), pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid (PPADS), suramin, and reactive blue 2 (RB-2) alone had no effect on intraocular pressure but attenuated responses to diadenosine polyphosphates by approximately 80%. It is concluded that Ap2A, Ap3A, and Ap5A increase intraocular pressure, and Ap4A decreases intraocular pressure via mechanisms that involve P2 receptors, and that Ap4A present in aqueous humor may serve to regulate intraocular pressure. Furthermore, we suggest that topical application of Ap4A to the cornea has therapeutic potential for lowering intraocular pressure, a major risk factor for glaucoma.     

The NMDA receptor antagonist MK-801 attenuates c-Fos expression in the lumbosacral spinal cord following repetitive noxious and non-noxious colorectal distention.

The effects of pretreatment with an NMDA receptor antagonist, MK-801, on c-Fos (Fos) expression in the lumbosacral spinal cord following repetitive, noxious (80 mmHg) or non-noxious (20 mmHg) colorectal distention (CRD) was examined immunocytochemically in awake and urethane anesthetized rats. In awake rats, noxious CRD induced Fos expression in the lumbosacral spinal cord. Pretreatment with MK-801 (0.1-1.0 mg/kg, i.p.) produced no change or an increase in noxious CRD induced-Fos expression and caused aversive side effects. In order to examine greater doses of MK-801, further experiments were performed in rats anesthetized with urethane. Both noxious and non-noxious CRD induced Fos in the lumbosacral spinal cord. Pretreatment with MK-801 (0.5, 1.0, 5.0 mg/kg, i.p.) dose-dependently attenuated noxious CRD-induced Fos by 20-40%. Five mg/kg MK-801 attenuated non-noxious CRD-induced Fos by 20%. Lesser doses did not significantly attenuate Fos expression. The laminar distribution of Fos following MK-801 pretreatment revealed a tendency towards the deeper laminae showing the greatest attenuation at the highest dose of MK-801. Protein plasma extravasation in the colon measured with Evan's blue dye showed no difference between rats without balloons, rats with balloons that were not distended and non-noxious CRD. There was significantly more extravasation following noxious CRD. Pretreatment with systemic MK-801 had no effect on plasma extravasation produced by noxious CRD. These data suggest that the induction of Fos in the lumbosacral spinal cord by noxious and non-noxious CRD is partially NMDA receptor mediated. However, NMDA receptor activation contributes significantly more to noxious than non-noxious CRD-induced Fos. Inflammation of the colon following noxious CRD likely contributes to sensitization of colonic afferents which may contribute to the increased NMDA receptor-mediated Fos following the noxious stimulus.     

Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF

Genetic manipulations of corticotropin-releasing factor (CRF)(1) and CRF(2) receptors have resulted in data suggesting that the CRF(2) receptor could mediate the effects of CRF on appetite or satiety. We have attempted to obtain pharmacological evidence for this hypothesis by comparing the ability of a high-affinity peptide, mixed CRF antagonist [cyclo 30-33,f12,L18,21E30, A32,K33]sucker fish urotensin (12-41)NH(2) [cUTSN (12-41)] with a small-molecule CRF(1)-selective antagonist, NBI-27914, and a CRF(2)-selective peptide antagonist, antisauvagine-30, to attenuate the anorexic effects of CRF. We also monitored other behaviors that accompanied CRF-induced anorexia. CRF-induced anorexia was significantly correlated with a reduction in locomotor activity and an increase in freezing behavior and piloerection. cUTSN (12-41) and antisauvagine-30 significantly attenuated the effects of CRF (0.04 nmol) on food intake along with the behavioral syndrome that accompanied anorexia. In contrast, NBI-27914 did not attenuate either of the above-mentioned CRF-induced phenomena when given centrally at doses ranging from 0.13 to 10 nmol/2.5 microl or when given orally at 20 to 40 mg/kg. Although these data support the hypothesis that the CRF(2) receptor mediates the appetite suppression induced by CRF, they also suggest that the CRF(2) receptor could mediate the stress-like behaviors that accompany CRF-induced appetite suppression.     

Evidence for Y1-receptor-mediated facilitatory, modulatory cotransmission by NPY in the rat anococcygeus muscle

The potential role of neuropeptide Y (NPY) as a neuromodulatory cotransmitter was investigated in rat anococcygeus muscle. The effects of NPY on contraction to norepinephrine or adrenergic nerve stimulation and on relaxation to nonadrenergic, noncholinergic nerve stimulation were analyzed. Norepinephrine-induced contraction was enhanced by NPY (0.1 microM). The Y1 receptor antagonist BIBP 3226 (1 microM) completely reversed this effect. NPY (0.01 or 0.1 microM) increased contractions induced by electrical field stimulation of sympathetic nerves. This increase was reduced by BIBP 3226 (1 microM), indicating Y1 receptor involvement. NPY (13-36) a Y2 receptor agonist, at 0.1 microM but not 0.01 microM, caused an increase of the nerve-induced contraction, which was reversed by BIBP 3226 (1 microM), indicating no Y2 receptor involvement. BIBP 3226 (1-1 microM) produced a concentration-dependent attenuation of nerve-mediated but not norepinephrine-mediated contraction. The reduction in nonadrenergic, noncholinergic nerve-induced relaxation to nerve stimulation by NPY (0.1 microM) was not affected by BIBP 3226 (1 microM). It is concluded that 1) exogenous NPY increases excitatory nerve-induced contraction mainly via a Y1 receptor-mediated effect on smooth muscle with a small non-Y1 receptor component due to blocking inhibitory nitrergic nerves and 2) endogenous NPY is a modulatory cotransmitter, which facilitates the primarily noradrenergic contractile responses to sympathetic nerve stimulation via smooth muscle Y1 receptors.     

Finding the optimal dose of vitamin K1 to treat vitamin K deficiency and to avoid anaphylactoid reactions

Vitamin K1 injection induces severe dose‐related anaphylactoid reactions and overdose for the treatment of vitamin K deficiency. We aimed to find an optimal and small dose of vitamin K1 injection to treat vitamin K deficiency and avoid anaphylactoid reactions in animal. Rats were administered a vitamin K‐deficient diet and gentamicin to establish vitamin K deficiency model. Behaviour tests were performed in beagle dogs to observe anaphylactoid reactions. The results showed an increased protein induced by vitamin K absence or antagonist II (PIVKA‐II) levels, a prolonging of prothrombin time (PT) and activated partial thromboplastin time (APTT) and a decrease in vitamin K‐dependent coagulation factor (F) II, VII, IX and X activities in the model group. In vitamin K1 0.01 mg/kg group, the liver vitamin K1 levels increased fivefold and the liver vitamin K2 levels increased to the normal amount. Coagulation markers PT, APTT, FVII and FIX activities returned to normal. Both in the 0.1 and 1.0 mg/kg vitamin K1 groups, coagulation functions completely returned to normal. Moreover, the amount of liver vitamin K1 was 40 (0.1 mg/kg) or 100 (1.0 mg/kg) times as in normal. Vitamin K2 was about 4 (0.1 mg/kg) or 5 (1.0 mg/kg) times as the normal amount. There was no obvious anaphylactoid symptom in dogs with the dose of 0.03 mg/kg, which is equivalent to the dose of 0.01 mg/kg in rats. These results demonstrated that a small dose of vitamin K1 is effective to improve vitamin K deficiency and to prevent anaphylactoid reactions, simultaneously.     

Neurochemical and behavioral effects of corticotropin-releasing factor in the ventral tegmental area of the rat

Corticotropin-releasing factor (CRF) is thought to have a neurotransmitter function in the mammalian central nervous system. The release of CRF into the hypothalamic-hypophyseal portal system in response to stress is known, and it has been suggested that CRF may function elsewhere in the central nervous system to promote stress-induced physiological and behavioral changes. Acute stress has been shown to activate dopamine (DA) neurons in the ventral tegmental area (VTA) that project to the prefrontal cortex. To determine whether CRF may act in the VTA to activate the mesocortical or mesolimbic DA systems, it was injected into the VTA of rats, and changes in spontaneous motor behavior and DA metabolism were measured. Intra-VTA injection of CRF produced a dose-dependent increase in horizontal and vertical photocell counts with a minimal effective dose of 0.01 and 0.1 nmol, respectively. In contrast, the minimal effective dose for CRF-stimulated motor behavior after injection into the lateral ventricles was 0.3 nmol for horizontal activity. Furthermore, in the open field, the behavioral profile of CRF (0.3 nmol) given intra-VTA differed from that observed after intraventricular injection. The motor stimulant effect of intra-VTA CRF was not blocked by pretreatment with the DA receptor antagonist haloperidol. After intra-VTA injection, CRF produced a dose-dependent decrease in DA metabolism in the prefrontal cortex. The decrease in DA metabolism in the prefrontal cortex was present at 30 and 60 min but not at 120 min after injection, and in the nucleus accumbens DA metabolism was increased only at 60 min after injection.(ABSTRACT TRUNCATED AT 250 WORDS)     

丹参酮ⅡA诱导NB4细胞凋亡与线粒体跨膜电位关系的研究

目的：研究丹参酮ⅡA（TanⅡA）诱导NB4细胞凋亡与线粒体跨膜电位（△Ψm）关系。方法：将NB4细胞分别用TanⅡA、As2O3,TanⅡA 1.0μg/ml环孢菌素A（CsA）和As2O3 1.0μg/mlCsA处理，多面手用光镜和透射电镜观察NB4细胞形态学变化；用流式细胞术分别测定G1期细胞百分率及PI和Rh123双染色后细胞的△Ψm。结果：NB4细胞经1．0和2．0μg/mlTanⅡA处理后的亚G1期细胞百分率无差异，但均高于0．5μg/ml组。NB4细胞经TanⅡA作用后，光镜和透射电镜下观察到典型的凋亡形态学特征；随着TanⅡA作用时间增加，NB4细胞凋亡数增加和△Ψm降低（P＜0．01），两者呈直线关系。CsA能抑制TanⅡA诱导NB4细胞△Ψm降低和凋亡细胞数增加（P＜0．01）。结论：TanⅡA诱导NB4细胞凋亡是通过使线粒体膜通透性转运孔开放，△Ψm降低来实现的；CsA能抑制这些效应。     

Long-term regulation of locus ceruleus sensitivity to corticotropin-releasing factor by swim stress.

Corticotropin-releasing factor (CRF) acts as a putative neurotransmitter in the locus ceruleus (LC) to mediate its activation by certain stressors. In this study, we quantified LC sensitivity to CRF 24 h after swim stress, at a time when behavioral depression that is sensitive to antidepressants is apparent. Rats were placed in a tank with 30 cm (swim stress) or 4 cm water and 24 h later, either behavior was monitored in a forced swim test or LC discharge was recorded. Swim stress rats were more immobile than control animals in the swim test. LC neurons of swim stress rats were sensitized to low doses of CRF (0.1-0.3 microgram i.c.v.) that were ineffective in control animals and were desensitized to higher doses. Swim stress selectively altered LC sensitivity to CRF because neither LC spontaneous discharge nor responses to other agents (e.g., carbachol, vasoactive intestinal peptide) were altered. Finally, the mechanism for sensitization was localized to the LC because neuronal activation by low doses of CRF was prevented by the intracerulear administration of a CRF antagonist. CRF dose-response curves were consistent with a two-site model with similar dissociation constants under control conditions but divergent dissociation constants after swim stress. The results suggest that swim stress (and perhaps other stressors) functionally alters CRF receptors that have an impact on LC activity. Stress-induced regulation of LC sensitivity to CRF may underlie behavioral aspects of stress-related psychiatric disorders.     

Analgesia and hyperalgesia from CRF receptor modulation in the central nervous system of Fischer and Lewis rats

This study examines the contribution of central corticotropin-releasing factor (CRF) to pain behavior. CRF is the principal modulator of the hypothalamo-pituitary-adrenal (HPA) axis, in addition to acting on many other areas of the central nervous system. We compared nociceptive thresholds (heat and mechanical) and pain behavior in response to a sustained stimulus (formalin test) between Fischer and Lewis rats that have different HPA axis activity. Intracerebroventricular (i.c.v.) administration of CRF produced dose-dependent antinociception at a lower dose in Lewis (40 ng, paw pinch 71+/-0 g) compared to Fischer rats (200 ng, 112+/-3 g). The antinociceptive effect of CRF was mostly preserved in adrenalectomized Fischer rats. The i.c.v. administration of the CRF receptor antagonist, astressin, had a hyperalgesic effect, suggesting that CRF is tonically active. Lewis rats required higher doses of astressin (5 ng, paw pinch 51+/-1 g) to show nociceptive effects compared to Fischer rats (1 ng, 79+/-1 g). Only Lewis rats vocalized during mechanical stimulus, and this behavior was prevented by diazepam or morphine but was worsened by CRF, despite its antinociceptive property. In the formalin test, CRF and astressin had the largest effect on the interphase suggesting that they act on the endogenous pain inhibitory system. CRF also increased anxiety/fear-like behaviors in the forced swim and predator odor tests. Our results establish that central CRF is a key modulator of pain behavior and indicates that CRF effects on nociception are largely independent of its mood modulating effect as well as its control of the HPA axis.     

Prenatal programming of renal salt wasting resets postnatal salt appetite, which drives food intake in the rat

Sodium retention has been proposed as the cause of hypertension in the LP rat (offspring exposed to a maternal low-protein diet in utero) model of developmental programming because of increased renal NKCC2 (Na+/K+/2Cl- co-transporter 2) expression. However, we have shown that LP rats excrete more rather than less sodium than controls, leading us to hypothesize that LP rats ingest more salt in order to maintain sodium balance. Rats were fed on either a 9% (low) or 18% (control) protein diet during pregnancy; male and female offspring were studied at 4 weeks of age. LP rats of both sexes held in metabolism cages excreted more sodium and urine than controls. When given water to drink, LP rats drank more and ate more food than controls, hence sodium intake matched excretion. However, when given a choice between saline and water to drink, the total volume of fluid ingested by LP rats fell to control levels, but the volume of saline taken was significantly larger [3.8±0.1 compared with 8.8±1.3 ml/24 h per 100 g of body weight in control and LP rats respectively; P<0.001]. Interestingly food intake also fell to control levels. Total body sodium content and ECF (extracellular fluid) volumes were greater in LP rats. These results show that prenatal programming of renal sodium wasting leads to a compensatory increase in salt appetite in LP rats. We speculate that the need to maintain salt homoeostasis following malnutrition in utero stimulates greater food intake, leading to accelerated growth and raised BP (blood pressure).     

Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats

The corticotropin-releasing factor (CRF) system mediates stress responses. Extrahypothalamic CRF1 receptor activation has anxiogenic-like properties, but anxiety-related functions of CRF2 receptors remain unclear. The present study determined the effects of intracerebroventricular administration of a CRF2 agonist, urocortin 3, on behavior of male Wistar rats in the shock-probe, social interaction, and defensive withdrawal tests of anxiety-like behavior. Equimolar doses of stressin1-A, a novel CRF1 agonist, were administered to separate rats. The effects of pyrazolo[1,5-a]-1,3,5-triazin-4-amine,8-[4-(bromo)-2-chlorophenyl]-N, N-bis(2-methoxyethyl)-2,7-dimethyl-(9Cl) (MJL-1-109-2), a CRF1 antagonist, on behavior in the shock-probe test also were studied. Stressin1-A increased anxiety-like behavior in the social interaction and shock-probe tests. Stressin1-A elicited behavioral activation and defensive burying at lower doses (0.04 nmol), but it increased freezing, grooming, and mounting at 25-fold higher (1-nmol) doses. Conversely, systemic administration of MJL-1-109-2 (10 mg/kg) had anxiolytic-like effects in the shock-probe test. Unlike stressin1-A or MJL-1-109-2, i.c.v. urocortin 3 infusion did not alter anxiety-like behavior in the shock-probe test across a range of doses that reduced locomotion and rearing and increased grooming. Urocortin 3 also did not decrease social interaction, but it decreased anxiety-like behavior in the defensive withdrawal test at a 2-nmol dose. Thus, i.c.v. administration of CRF1 and CRF2 agonists produced differential, but not opposite, effects on anxiety-like behavior. Urocortin 3 (i.c.v.) did not consistently decrease or increase anxiety-like behavior, the latter unlike effects seen previously after local microinjection of CRF2 agonists into the septum or raphe. With increasing CRF1 activation, however, the behavioral expression of anxiety qualitatively changes from "coping" to "noncoping" and offensive, agonistic behaviors.     

Attenuation of the alcohol preference of C57BL/6 mice during chronic renal failure

The C57BL/6 inbred mouse strain is known for its strong, genetically determined preference for alcohol over water. In this study we examined the voluntary alcohol consumption (VAC) of C57BL/6 mice during chronic renal failure (CRF). Two weeks after the surgical induction of renal failure, CRF mice, together with normal and sham-operated control mice, were submitted to a standard 24-day VAC protocol. The mice were offered water for the first 6 days (period of acclimatization), alcohol (10% ethanol solution) for the next 4 days (period of forced alcohol exposure), and a choice between water and alcohol for the last 14 days (VAC period). The results (mean +/- SEM) obtained from the last 8 days of the VAC period were significantly different (P <.05) between CRF mice and the 2 control groups. As expected, CRF mice had a higher total fluid intake than did normal and sham-operated controls (9.5 +/- 0.2 vs 5.4 +/- 0.2 and 5.4 +/- 0.2 g/d). Surprisingly, despite their increased total fluid consumption, CRF mice nearly abolished their absolute alcohol intake compared with that of both control groups (3.2 +/- 0.5 vs 13.1 +/- 0.8 and 14.2 +/- 1.1 g alcohol/kg body wt/d). The resulting alcohol preference ratio (g alcohol/g total fluid) was markedly decreased in the CRF mice compared with that in both control groups (0.09 +/- 0.01 vs 0.62 +/- 0.03 and 0.64 +/- 0.05). We conclude that the innate alcohol preference of C57BL/6 mice is nearly abolished during CRF. Additional studies to clarify the mechanism of this striking change in drinking pattern are required, with special emphasis on the possible role of angiotensin II, which is involved in thirst regulation and known to reduce the alcohol consumption of normal alcohol-preferring rats.     

不同剂量神经生长因子对神经源性疼痛大鼠脊髓Fos蛋白的影响

背景:神经生长因子对神经元的存活、生长发育、分化、再生和功能维持起到调控作用.目的:进一步验证不同剂量神经生长因子对神经源性痛大鼠的治疗作用以及对脊髓中Fos蛋白的影响.设计、地点:随机对照动物实验,在上海第九人民医院完成.材料:健康成年雄性Wistar大鼠72只,体质量180-200 g,随机分为4组,模型组及腹腔注射神经生长因子4, 8,16 μg组,每组18只.方法:72只大鼠结扎左侧坐骨神经制备坐骨神经慢性缩窄性损伤模型;腹腔注射神经生长因子4, 8,16 μg组,造模后分别腹腔注射神经生长因子4,8,16 Pg/(kg·d).主要观察指标:①于术前和术后第1,2,3,5,7,10,14天进行行为学观察和机械性痛阈测定.②于术后第2.7,14天各组分别处死大鼠各6只,取脊髓,应用免疫组织化学方法和图像分析系统检测脊髓中Fos蛋白的表达.结果:模型组大鼠术后出现自发抬足、舔足等自发痛表现,术后第3天起开始出现痛阈下降,第14天达最低值,而注射神经生长因子组大鼠没有自发痛表现,没有出现机械性痛阈的低常期,第10,14天模型组大鼠痛阈与其余各组比较差异有显著性意义(P<0.05).4组大鼠术后第1天机械性痛阈普遍升高;注射神经生长因子16 Pg组大鼠术后第1天机械性痛闽比其他各组低(P<0.01),第2天机械性痛阈恢复至术前水平,低于注射神经生长因子4 Pg组(P<0.05).术后模型组大鼠脊髓Fos蛋白表达进行性升高,而其他各组大鼠脊髓中仅有少量Fos阳性神经元,模型组与其余各组比较差异显著(P<0.01).术后第2天注射神经生长因子16 μg组大鼠脊髓Fos蛋白表达最低,与模型组和注射神经生长因子4 Pg组比较,差异有显著性意义(P<0.01).结论:神经生长因子对大鼠神经源性痛有治疗作用,且大剂量较小剂量作用更为明显,其机制可能与抑制脊髓中Fos蛋白表达有关.